Acumen Pharmaceuticals (NASDAQ: ABOS) director awarded RSUs and options

Rhea-AI Filing Summary

Acumen Pharmaceuticals director George Golumbeski received new equity compensation awards. He was granted 35,500 restricted stock units, each representing one share of common stock, and a stock option covering 53,250 shares at an exercise price of $2.29 per share.

The RSUs and the option will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to his continuous service. After these grants, he directly holds 35,500 shares of common stock and 53,250 stock options from this award.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Golumbeski George

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	53,250	$0.00	--
Grant/Award	Common Stock	35,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 53,250 shares (Direct, null); Common Stock — 35,500 shares (Direct, null)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

RSU award size: 35,500 shares Option grant size: 53,250 shares Option exercise price: $2.29 per share +3 more

6 metrics

RSU award size 35,500 shares Restricted stock units granted to director on June 3, 2026

Option grant size 53,250 shares Stock option covering common stock granted on June 3, 2026

Option exercise price $2.29 per share Conversion/exercise price for new stock option

Shares held after grant 35,500 shares Total common stock directly owned after RSU award

Options held after grant 53,250 options Total options from this award following transaction

Option expiration June 3, 2036 Expiration date of the stock option grant

Key Terms

restricted stock unit ("RSU"), Stock Option (right to buy), exercise price, continuous service, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right..."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an underlying security of Common Stock..."

exercise price financial

"conversion or exercise price of 2.2900 per share for the option grant..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

annual stockholder meeting financial

"on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Golumbeski George

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MASSACHUSETTS 02465

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		35,500(1)	A	$0	35,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.29	06/03/2026		A		53,250		(2)	06/03/2036	Common Stock	53,250	$0	53,250	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Acumen Pharmaceuticals (ABOS) director George Golumbeski receive?

He received 35,500 restricted stock units and a stock option for 53,250 shares. The option has a $2.29 exercise price and both awards are part of his equity compensation package as a director.

How do the new RSUs for Acumen Pharmaceuticals (ABOS) vest?

The 35,500 RSUs vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, provided George Golumbeski maintains continuous service with Acumen Pharmaceuticals through that date.

What are the terms of the new stock option granted by Acumen Pharmaceuticals (ABOS)?

The stock option covers 53,250 shares of common stock at $2.29 per share. It will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, assuming continuous service.

How many Acumen Pharmaceuticals (ABOS) shares does George Golumbeski hold after this Form 4?

Following the grants, he directly holds 35,500 shares of common stock and a stock option for 53,250 additional shares. These holdings reflect his equity position from this reported award.

When do George Golumbeski’s Acumen Pharmaceuticals (ABOS) options expire?

The stock option granted on this Form 4 expires on June 3, 2036. It vests earlier, in full, on the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to continuous service.